- Iridex Reports First Quarter 2024 Financial Results
- Iridex to Report First Quarter 2024 Financial Results on May 14, 2024
- Iridex Reports Fourth Quarter and Full Year 2023 Financial Results
- Iridex Schedules Fourth Quarter and Full Year 2023 Financial Results and Update on Strategic Review Process for March 26, 2024
- Iridex Corporation Receives European Patent on MicroPulse Technology
- Iridex Announces First Patient Enrollment in MicroPulse® TLT Clinical Study Conducted in Collaboration with Imperial College Healthcare NHS Trust
- Iridex Launches New Iridex 532® and Iridex 577® Lasers in US Market Marking 35 Years of Laser Innovation in Treating Retina Disorders & Glaucoma
- Iridex Confirms Medicare Administrative Contractors Retired Local Coverage Determinations that Restricted Cyclophotocoagulation
- Iridex Corporation Announces Successful Appeal for Revision of Recent Medicare LCDs to Provide Broader Coverage of Cyclophotocoagulation
- Iridex Reports Third Quarter 2023 Financial Results and Business Update
More ▼
Key statistics
As of last trade IRIDEX Corp (IRIX:NMQ) traded at 2.50, -31.51% below its 52-week high of 3.65, set on Apr 09, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.56 |
---|---|
High | 2.56 |
Low | 2.42 |
Bid | 2.45 |
Offer | 2.50 |
Previous close | 2.49 |
Average volume | 62.23k |
---|---|
Shares outstanding | 16.25m |
Free float | 12.23m |
P/E (TTM) | -- |
Market cap | 40.47m USD |
EPS (TTM) | -0.6759 USD |
Data delayed at least 15 minutes, as of May 24 2024 20:12 BST.
More ▼